



Global Prostate Cancer Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-19	196	PDF

Single User	Multi User	Enterprise
USD 3,950	USD 5,925	USD 7,900

Description

The global Prostate Cancer Vaccines market is projected to grow from US\$ million in 2026 to US\$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Prostate Cancer Vaccines is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prostate Cancer Vaccines is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Prostate Cancer Vaccines is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Prostate Cancer Vaccines is projected to increase from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Prostate Cancer Vaccines include Pfizer Inc., Vaccitech, Vaccibody AS, Ultimovacs, UbiVac, SOTIO, Sensei Biotherapeutics, Oncovir Inc. and OncBioMune Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prostate Cancer Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostate Cancer Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostate Cancer Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prostate Cancer Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Prostate Cancer Vaccines Segment by Company

- Pfizer Inc.
- Vaccitech
- Vaccibody AS

Ultimovacs
UbiVac
SOTIO
Sensei Biotherapeutics
Oncovir Inc.
OncBioMune Pharmaceuticals
Momotaro-Gene Inc.
Mediolanum Farmaceutici
Medigene AG
Dendreon Corporation
Curevac AG
Cleveland BioLabs Inc.
Bavarian Nordic
AlphaVax Inc.
Advaxis immunotherapies
Advantagene

Prostate Cancer Vaccines Segment by Type

Tablet
Injection

Prostate Cancer Vaccines Segment by Application

Hospital
Clinic
Others

Prostate Cancer Vaccines Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Provides an overview of the Prostate Cancer Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2:

Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3:

Detailed analysis of Prostate Cancer Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6:

Sales of Prostate Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7:

Revenue of Prostate Cancer Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Concluding Insights of the report

Table of Contents

1 Market Overview

- 1.1 Product Definition
- 1.2 Global Prostate Cancer Vaccines Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Prostate Cancer Vaccines Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Prostate Cancer Vaccines Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Prostate Cancer Vaccines Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives

2 Global Prostate Cancer Vaccines Market Dynamics

- 2.1 Prostate Cancer Vaccines Industry Trends
- 2.2 Prostate Cancer Vaccines Industry Drivers
- 2.3 Prostate Cancer Vaccines Industry Opportunities and Challenges
- 2.4 Prostate Cancer Vaccines Industry Restraints

3 Prostate Cancer Vaccines Market by Manufacturers

- 3.1 Global Prostate Cancer Vaccines Revenue by Manufacturers (2021-2026)
- 3.2 Global Prostate Cancer Vaccines Sales by Manufacturers (2021-2026)
- 3.3 Global Prostate Cancer Vaccines Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Prostate Cancer Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Prostate Cancer Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Prostate Cancer Vaccines Manufacturers, Product Type & Application
- 3.7 Global Prostate Cancer Vaccines Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
 - 3.8.1 Global Prostate Cancer Vaccines Market CR5 and HHI
 - 3.8.2 Global Top 5 and 10 Prostate Cancer Vaccines Players Market Share by Revenue in 2025
 - 3.8.3 2025 Prostate Cancer Vaccines Tier 1, Tier 2, and Tier 3

4 Prostate Cancer Vaccines Market by Type

- 4.1 Prostate Cancer Vaccines Type Introduction
 - 4.1.1 Tablet
 - 4.1.2 Injection
- 4.2 Global Prostate Cancer Vaccines Sales by Type
 - 4.2.1 Global Prostate Cancer Vaccines Sales by Type (2021 VS 2025 VS 2032)
 - 4.2.2 Global Prostate Cancer Vaccines Sales by Type (2021-2032)
 - 4.2.3 Global Prostate Cancer Vaccines Sales Market Share by Type (2021-2032)
- 4.3 Global Prostate Cancer Vaccines Revenue by Type
 - 4.3.1 Global Prostate Cancer Vaccines Revenue by Type (2021 VS 2025 VS 2032)
 - 4.3.2 Global Prostate Cancer Vaccines Revenue by Type (2021-2032)
 - 4.3.3 Global Prostate Cancer Vaccines Revenue Market Share by Type (2021-2032)

5 Prostate Cancer Vaccines Market by Application

- 5.1 Prostate Cancer Vaccines Application Introduction
 - 5.1.1 Hospital
 - 5.1.2 Clinic
 - 5.1.3 Others

- 5.2 Global Prostate Cancer Vaccines Sales by Application
 - 5.2.1 Global Prostate Cancer Vaccines Sales by Application (2021 VS 2025 VS 2032)
 - 5.2.2 Global Prostate Cancer Vaccines Sales by Application (2021-2032)
 - 5.2.3 Global Prostate Cancer Vaccines Sales Market Share by Application (2021-2032)
- 5.3 Global Prostate Cancer Vaccines Revenue by Application
 - 5.3.1 Global Prostate Cancer Vaccines Revenue by Application (2021 VS 2025 VS 2032)
 - 5.3.2 Global Prostate Cancer Vaccines Revenue by Application (2021-2032)
 - 5.3.3 Global Prostate Cancer Vaccines Revenue Market Share by Application (2021-2032)

6 Global Prostate Cancer Vaccines Sales by Region

- 6.1 Global Prostate Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032
 - 6.2 Global Prostate Cancer Vaccines Sales by Region (2021-2032)
 - 6.2.1 Global Prostate Cancer Vaccines Sales by Region (2021-2026)
 - 6.2.2 Global Prostate Cancer Vaccines Sales Forecasted by Region (2027-2032)
 - 6.3 North America
 - 6.3.1 North America Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.3.2 North America Prostate Cancer Vaccines Sales by Country (2021-2032)
 - 6.3.3 U.S.
 - 6.3.4 Canada
 - 6.3.5 Mexico
 - 6.4 Europe
 - 6.4.1 Europe Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.4.2 Europe Prostate Cancer Vaccines Sales by Country (2021-2032)
 - 6.4.3 Germany
 - 6.4.4 France
 - 6.4.5 U.K.
 - 6.4.6 Italy
 - 6.4.7 Netherlands
 - 6.5 Asia Pacific
 - 6.5.1 Asia Pacific Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.5.2 Asia Pacific Prostate Cancer Vaccines Sales by Country (2021-2032)
 - 6.5.3 China
 - 6.5.4 Japan
 - 6.5.5 South Korea
 - 6.5.6 Southeast Asia
 - 6.5.7 India
 - 6.5.8 Australia
 - 6.6 South America, Middle East and Africa
 - 6.6.1 South America, Middle East and Africa Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
 - 6.6.2 South America, Middle East and Africa Prostate Cancer Vaccines Sales by Country (2021-2032)
 - 6.6.3 Brazil
 - 6.6.4 South Africa
 - 6.6.5 Saudi Arabia
 - 6.6.6 Turkey
 - 6.6.6 Argentina
 - 6.6.6 UAE
 - 6.6.6 Egypt
 - 6.6.6 Chile
-

7 Global Prostate Cancer Vaccines Revenue by Region

- 7.1 Global Prostate Cancer Vaccines Revenue by Region
 - 7.1.1 Global Prostate Cancer Vaccines Revenue by Region: 2021 VS 2025 VS 2032
 - 7.1.2 Global Prostate Cancer Vaccines Revenue by Region (2021-2026)
 - 7.1.3 Global Prostate Cancer Vaccines Revenue by Region (2027-2032)
 - 7.1.4 Global Prostate Cancer Vaccines Revenue Market Share by Region (2021-2032)
- 7.2 North America
 - 7.2.1 North America Prostate Cancer Vaccines Revenue (2021-2032)
 - 7.2.2 North America Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
 - 7.3.1 Europe Prostate Cancer Vaccines Revenue (2021-2032)
 - 7.3.2 Europe Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
 - 7.4.1 Asia-Pacific Prostate Cancer Vaccines Revenue (2021-2032)
 - 7.4.2 Asia-Pacific Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
 - 7.5.1 South America, Middle East and Africa Prostate Cancer Vaccines Revenue (2021-2032)
 - 7.5.2 South America, Middle East and Africa Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032

8 Company Profiles

- 8.1 Pfizer Inc.
 - 8.1.1 Pfizer Inc. Company Information
 - 8.1.2 Pfizer Inc. Business Overview
 - 8.1.3 Pfizer Inc. Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.1.4 Pfizer Inc. Prostate Cancer Vaccines Product Portfolio
 - 8.1.5 Pfizer Inc. Recent Developments
- 8.2 Vaccitech
 - 8.2.1 Vaccitech Company Information
 - 8.2.2 Vaccitech Business Overview
 - 8.2.3 Vaccitech Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.2.4 Vaccitech Prostate Cancer Vaccines Product Portfolio
 - 8.2.5 Vaccitech Recent Developments
- 8.3 Vaccibody AS
 - 8.3.1 Vaccibody AS Company Information
 - 8.3.2 Vaccibody AS Business Overview
 - 8.3.3 Vaccibody AS Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.3.4 Vaccibody AS Prostate Cancer Vaccines Product Portfolio
 - 8.3.5 Vaccibody AS Recent Developments
- 8.4 Ultimovacs
 - 8.4.1 Ultimovacs Company Information
 - 8.4.2 Ultimovacs Business Overview
 - 8.4.3 Ultimovacs Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
 - 8.4.4 Ultimovacs Prostate Cancer Vaccines Product Portfolio
 - 8.4.5 Ultimovacs Recent Developments
- 8.5 UbiVac
 - 8.5.1 UbiVac Company Information
 - 8.5.2 UbiVac Business Overview

8.5.3 UbiVac Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.5.4 UbiVac Prostate Cancer Vaccines Product Portfolio

8.5.5 UbiVac Recent Developments

8.6 SOTIO

8.6.1 SOTIO Company Information

8.6.2 SOTIO Business Overview

8.6.3 SOTIO Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.6.4 SOTIO Prostate Cancer Vaccines Product Portfolio

8.6.5 SOTIO Recent Developments

8.7 Sensei Biotherapeutics

8.7.1 Sensei Biotherapeutics Company Information

8.7.2 Sensei Biotherapeutics Business Overview

8.7.3 Sensei Biotherapeutics Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.7.4 Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolio

8.7.5 Sensei Biotherapeutics Recent Developments

8.8 Oncovir Inc.

8.8.1 Oncovir Inc. Company Information

8.8.2 Oncovir Inc. Business Overview

8.8.3 Oncovir Inc. Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.8.4 Oncovir Inc. Prostate Cancer Vaccines Product Portfolio

8.8.5 Oncovir Inc. Recent Developments

8.9 OncBioMune Pharmaceuticals

8.9.1 OncBioMune Pharmaceuticals Company Information

8.9.2 OncBioMune Pharmaceuticals Business Overview

8.9.3 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.9.4 OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolio

8.9.5 OncBioMune Pharmaceuticals Recent Developments

8.10 Momotaro-Gene Inc.

8.10.1 Momotaro-Gene Inc. Company Information

8.10.2 Momotaro-Gene Inc. Business Overview

8.10.3 Momotaro-Gene Inc. Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.10.4 Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolio

8.10.5 Momotaro-Gene Inc. Recent Developments

8.11 Mediolanum Farmaceutici

8.11.1 Mediolanum Farmaceutici Company Information

8.11.2 Mediolanum Farmaceutici Business Overview

8.11.3 Mediolanum Farmaceutici Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.11.4 Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolio

8.11.5 Mediolanum Farmaceutici Recent Developments

8.12 Medigene AG

8.12.1 Medigene AG Company Information

8.12.2 Medigene AG Business Overview

8.12.3 Medigene AG Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.12.4 Medigene AG Prostate Cancer Vaccines Product Portfolio

8.12.5 Medigene AG Recent Developments

8.13 Dendreon Corporation

8.13.1 Dendreon Corporation Company Information

8.13.2 Dendreon Corporation Business Overview

8.13.3 Dendreon Corporation Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.13.4 Dendreon Corporation Prostate Cancer Vaccines Product Portfolio

8.13.5 Dendreon Corporation Recent Developments

8.14 Curevac AG

8.14.1 Curevac AG Company Information

8.14.2 Curevac AG Business Overview

8.14.3 Curevac AG Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.14.4 Curevac AG Prostate Cancer Vaccines Product Portfolio

8.14.5 Curevac AG Recent Developments

8.15 Cleveland BioLabs Inc.

8.15.1 Cleveland BioLabs Inc. Company Information

8.15.2 Cleveland BioLabs Inc. Business Overview

8.15.3 Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.15.4 Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolio

8.15.5 Cleveland BioLabs Inc. Recent Developments

8.16 Bavarian Nordic

8.16.1 Bavarian Nordic Company Information

8.16.2 Bavarian Nordic Business Overview

8.16.3 Bavarian Nordic Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.16.4 Bavarian Nordic Prostate Cancer Vaccines Product Portfolio

8.16.5 Bavarian Nordic Recent Developments

8.17 AlphaVax Inc.

8.17.1 AlphaVax Inc. Company Information

8.17.2 AlphaVax Inc. Business Overview

8.17.3 AlphaVax Inc. Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.17.4 AlphaVax Inc. Prostate Cancer Vaccines Product Portfolio

8.17.5 AlphaVax Inc. Recent Developments

8.18 Advaxis immunotherapies

8.18.1 Advaxis immunotherapies Company Information

8.18.2 Advaxis immunotherapies Business Overview

8.18.3 Advaxis immunotherapies Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.18.4 Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolio

8.18.5 Advaxis immunotherapies Recent Developments

8.19 Advantagene

8.19.1 Advantagene Company Information

8.19.2 Advantagene Business Overview

8.19.3 Advantagene Prostate Cancer Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)

8.19.4 Advantagene Prostate Cancer Vaccines Product Portfolio

8.19.5 Advantagene Recent Developments

9 Value Chain and Sales Channels Analysis

9.1 Prostate Cancer Vaccines Value Chain Analysis

9.1.1 Prostate Cancer Vaccines Key Raw Materials

9.1.2 Raw Materials Key Suppliers

9.1.3 Manufacturing Cost Structure

9.1.4 Prostate Cancer Vaccines Production Mode & Process

9.2 Prostate Cancer Vaccines Sales Channels Analysis

9.2.1 Direct Comparison with Distribution Share

9.2.2 Prostate Cancer Vaccines Distributors

10 Concluding Insights

11 Appendix

- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
 - 11.5.1 Secondary Sources
 - 11.5.2 Primary Sources
- 11.6 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Prostate Cancer Vaccines Industry Trends
- Table 2: Prostate Cancer Vaccines Industry Drivers
- Table 3: Prostate Cancer Vaccines Industry Opportunities and Challenges
- Table 4: Prostate Cancer Vaccines Industry Restraints
- Table 5: Global Prostate Cancer Vaccines Revenue by Manufacturers (US\$ Million) & (2021-2026)
- Table 6: Global Prostate Cancer Vaccines Revenue Market Share by Manufacturers (2021-2026)
- Table 7: Global Prostate Cancer Vaccines Sales by Manufacturers (K Units) & (2021-2026)
- Table 8: Global Prostate Cancer Vaccines Sales Market Share by Manufacturers
- Table 9: Global Prostate Cancer Vaccines Average Sales Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 10: Global Prostate Cancer Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- Table 11: Global Prostate Cancer Vaccines Key Manufacturers Manufacturing Sites & Headquarters
- Table 12: Global Prostate Cancer Vaccines Manufacturers, Product Type & Application
- Table 13: Global Prostate Cancer Vaccines Manufacturers Establishment Date
- Table 14: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 15: Global Prostate Cancer Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
- Table 16: Major Manufacturers of Tablet
- Table 17: Major Manufacturers of Injection
- Table 18: Global Prostate Cancer Vaccines Sales by Type 2021 VS 2025 VS 2032 (K Units)
- Table 19: Global Prostate Cancer Vaccines Sales by Type (2021-2026) & (K Units)
- Table 20: Global Prostate Cancer Vaccines Sales by Type (2027-2032) & (K Units)
- Table 21: Global Prostate Cancer Vaccines Sales Market Share by Type (2021-2026)
- Table 22: Global Prostate Cancer Vaccines Sales Market Share by Type (2027-2032)
- Table 23: Global Prostate Cancer Vaccines Revenue by Type 2021 VS 2025 VS 2032 (K Units)
- Table 24: Global Prostate Cancer Vaccines Revenue by Type (2021-2026) & (K Units)
- Table 25: Global Prostate Cancer Vaccines Revenue by Type (2027-2032) & (K Units)
- Table 26: Global Prostate Cancer Vaccines Revenue Market Share by Type (2021-2026)
- Table 27: Global Prostate Cancer Vaccines Revenue Market Share by Type (2027-2032)
- Table 28: Major Manufacturers of Hospital
- Table 29: Major Manufacturers of Clinic
- Table 30: Major Manufacturers of Others
- Table 31: Global Prostate Cancer Vaccines Sales by Application 2021 VS 2025 VS 2032 (K Units)
- Table 32: Global Prostate Cancer Vaccines Sales by Application (2021-2026) & (K Units)
- Table 33: Global Prostate Cancer Vaccines Sales by Application (2027-2032) & (K Units)
- Table 34: Global Prostate Cancer Vaccines Sales Market Share by Application (2021-2026)
- Table 35: Global Prostate Cancer Vaccines Sales Market Share by Application (2027-2032)
- Table 36: Global Prostate Cancer Vaccines Revenue by Application 2021 VS 2025 VS 2032 (K Units)
- Table 37: Global Prostate Cancer Vaccines Revenue by Application (2021-2026) & (K Units)
- Table 38: Global Prostate Cancer Vaccines Revenue by Application (2027-2032) & (K Units)
- Table 39: Global Prostate Cancer Vaccines Revenue Market Share by Application (2021-2026)
- Table 40: Global Prostate Cancer Vaccines Revenue Market Share by Application (2027-2032)
- Table 41: Global Prostate Cancer Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units)
- Table 42: Global Prostate Cancer Vaccines Sales by Region (2021-2026) & (K Units)
- Table 43: Global Prostate Cancer Vaccines Sales Market Share by Region (2021-2026)
- Table 44: Global Prostate Cancer Vaccines Sales Forecasted by Region (2027-2032) & (K Units)
- Table 45: Global Prostate Cancer Vaccines Sales Forecasted Market Share by Region (2027-2032)
- Table 46: North America Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
- Table 47: North America Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units)
- Table 48: North America Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units)
- Table 49: Europe Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
- Table 50: Europe Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units)
- Table 51: Europe Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units)
- Table 52: Asia Pacific Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
- Table 53: Asia Pacific Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units)
- Table 54: Asia Pacific Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units)

- Table 55: South America, Middle East and Africa Prostate Cancer Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units)
- Table 56: South America, Middle East and Africa Prostate Cancer Vaccines Sales by Country (2021-2026) & (K Units)
- Table 57: South America, Middle East and Africa Prostate Cancer Vaccines Sales by Country (2027-2032) & (K Units)
- Table 58: Global Prostate Cancer Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 59: Global Prostate Cancer Vaccines Revenue by Region (2021-2026) & (US\$ Million)
- Table 60: Global Prostate Cancer Vaccines Revenue by Region (2027-2032) & (US\$ Million)
- Table 61: Global Prostate Cancer Vaccines Revenue Market Share by Region (2021-2026)
- Table 62: Global Prostate Cancer Vaccines Revenue Market Share by Region (2027-2032)
- Table 63: Pfizer Inc. Company Information
- Table 64: Pfizer Inc. Business Overview
- Table 65: Pfizer Inc. Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 66: Pfizer Inc. Prostate Cancer Vaccines Product Portfolio
- Table 67: Pfizer Inc. Recent Development
- Table 68: Vaccitech Company Information
- Table 69: Vaccitech Business Overview
- Table 70: Vaccitech Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 71: Vaccitech Prostate Cancer Vaccines Product Portfolio
- Table 72: Vaccitech Recent Development
- Table 73: Vaccibody AS Company Information
- Table 74: Vaccibody AS Business Overview
- Table 75: Vaccibody AS Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 76: Vaccibody AS Prostate Cancer Vaccines Product Portfolio
- Table 77: Vaccibody AS Recent Development
- Table 78: Ultimovacs Company Information
- Table 79: Ultimovacs Business Overview
- Table 80: Ultimovacs Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 81: Ultimovacs Prostate Cancer Vaccines Product Portfolio
- Table 82: Ultimovacs Recent Development
- Table 83: UbiVac Company Information
- Table 84: UbiVac Business Overview
- Table 85: UbiVac Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 86: UbiVac Prostate Cancer Vaccines Product Portfolio
- Table 87: UbiVac Recent Development
- Table 88: SOTIO Company Information
- Table 89: SOTIO Business Overview
- Table 90: SOTIO Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 91: SOTIO Prostate Cancer Vaccines Product Portfolio
- Table 92: SOTIO Recent Development
- Table 93: Sensei Biotherapeutics Company Information
- Table 94: Sensei Biotherapeutics Business Overview
- Table 95: Sensei Biotherapeutics Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 96: Sensei Biotherapeutics Prostate Cancer Vaccines Product Portfolio
- Table 97: Sensei Biotherapeutics Recent Development
- Table 98: Oncovir Inc. Company Information
- Table 99: Oncovir Inc. Business Overview
- Table 100: Oncovir Inc. Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 101: Oncovir Inc. Prostate Cancer Vaccines Product Portfolio
- Table 102: Oncovir Inc. Recent Development
- Table 103: OncBioMune Pharmaceuticals Company Information
- Table 104: OncBioMune Pharmaceuticals Business Overview
- Table 105: OncBioMune Pharmaceuticals Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 106: OncBioMune Pharmaceuticals Prostate Cancer Vaccines Product Portfolio
- Table 107: OncBioMune Pharmaceuticals Recent Development
- Table 108: Momotaro-Gene Inc. Company Information
- Table 109: Momotaro-Gene Inc. Business Overview

- Table 110: Momotaro-Gene Inc. Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 111: Momotaro-Gene Inc. Prostate Cancer Vaccines Product Portfolio
- Table 112: Momotaro-Gene Inc. Recent Development
- Table 113: Mediolanum Farmaceutici Company Information
- Table 114: Mediolanum Farmaceutici Business Overview
- Table 115: Mediolanum Farmaceutici Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 116: Mediolanum Farmaceutici Prostate Cancer Vaccines Product Portfolio
- Table 117: Mediolanum Farmaceutici Recent Development
- Table 118: Medigene AG Company Information
- Table 119: Medigene AG Business Overview
- Table 120: Medigene AG Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 121: Medigene AG Prostate Cancer Vaccines Product Portfolio
- Table 122: Medigene AG Recent Development
- Table 123: Dendreon Corporation Company Information
- Table 124: Dendreon Corporation Business Overview
- Table 125: Dendreon Corporation Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 126: Dendreon Corporation Prostate Cancer Vaccines Product Portfolio
- Table 127: Dendreon Corporation Recent Development
- Table 128: Curevac AG Company Information
- Table 129: Curevac AG Business Overview
- Table 130: Curevac AG Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 131: Curevac AG Prostate Cancer Vaccines Product Portfolio
- Table 132: Curevac AG Recent Development
- Table 133: Cleveland BioLabs Inc. Company Information
- Table 134: Cleveland BioLabs Inc. Business Overview
- Table 135: Cleveland BioLabs Inc. Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 136: Cleveland BioLabs Inc. Prostate Cancer Vaccines Product Portfolio
- Table 137: Cleveland BioLabs Inc. Recent Development
- Table 138: Bavarian Nordic Company Information
- Table 139: Bavarian Nordic Business Overview
- Table 140: Bavarian Nordic Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 141: Bavarian Nordic Prostate Cancer Vaccines Product Portfolio
- Table 142: Bavarian Nordic Recent Development
- Table 143: AlphaVax Inc. Company Information
- Table 144: AlphaVax Inc. Business Overview
- Table 145: AlphaVax Inc. Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 146: AlphaVax Inc. Prostate Cancer Vaccines Product Portfolio
- Table 147: AlphaVax Inc. Recent Development
- Table 148: Advaxis immunotherapies Company Information
- Table 149: Advaxis immunotherapies Business Overview
- Table 150: Advaxis immunotherapies Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 151: Advaxis immunotherapies Prostate Cancer Vaccines Product Portfolio
- Table 152: Advaxis immunotherapies Recent Development
- Table 153: Advantagene Company Information
- Table 154: Advantagene Business Overview
- Table 155: Advantagene Prostate Cancer Vaccines Sales (K Units), Price (US\$/Unit), Revenue (US\$ Million) and Gross Margin (2021-2026)
- Table 156: Advantagene Prostate Cancer Vaccines Product Portfolio
- Table 157: Advantagene Recent Development
- Table 158: Key Raw Materials
- Table 159: Raw Materials Key Suppliers
- Table 160: Prostate Cancer Vaccines Distributors List
- Table 161: Prostate Cancer Vaccines Customers List
- Table 162: Research Programs/Design for This Report
- Table 163: Authors List of This Report
- Table 164: Secondary Sources

- Table 165: Primary Sources

List of Figures:

- Figure 1: Prostate Cancer Vaccines Product Image
- Figure 2: Global Prostate Cancer Vaccines Market Size (US\$ Million), 2021 VS 2025 VS 2032
- Figure 3: Global Prostate Cancer Vaccines Market Size (2021-2032) & (US\$ Million)
- Figure 4: Global Prostate Cancer Vaccines Sales (2021-2032) & (K Units)
- Figure 5: Global Prostate Cancer Vaccines Average Price (US\$/Unit) & (2021-2032)
- Figure 6: Global Top 5 and 10 Prostate Cancer Vaccines Players Market Share by Revenue in 2025
- Figure 7: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 8: Tablet Image
- Figure 9: Injection Image
- Figure 10: Global Prostate Cancer Vaccines Sales by Type (2021 VS 2025 VS 2032) & (K Units)
- Figure 11: Global Prostate Cancer Vaccines Sales Market Share 2021 VS 2025 VS 2032
- Figure 12: Global Prostate Cancer Vaccines Sales Market Share by Type (2021-2032)
- Figure 13: Global Prostate Cancer Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (K Units)
- Figure 14: Global Prostate Cancer Vaccines Revenue Market Share 2021 VS 2025 VS 2032
- Figure 15: Global Prostate Cancer Vaccines Revenue Market Share by Type (2021-2032)
- Figure 16: Hospital Image
- Figure 17: Clinic Image
- Figure 18: Others Image
- Figure 19: Global Prostate Cancer Vaccines Sales by Application (2021 VS 2025 VS 2032) & (K Units)
- Figure 20: Global Prostate Cancer Vaccines Sales Market Share 2021 VS 2025 VS 2032
- Figure 21: Global Prostate Cancer Vaccines Sales Market Share by Application (2021-2032)
- Figure 22: Global Prostate Cancer Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (K Units)
- Figure 23: Global Prostate Cancer Vaccines Revenue Market Share 2021 VS 2025 VS 2032
- Figure 24: Global Prostate Cancer Vaccines Revenue Market Share by Application (2021-2032)
- Figure 25: North America Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 26: North America Prostate Cancer Vaccines Sales Market Share by Country (2021-2032)
- Figure 27: U.S. Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 28: Canada Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 29: Mexico Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 30: Europe Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 31: Europe Prostate Cancer Vaccines Sales Market Share by Country (2021-2032)
- Figure 32: Germany Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 33: France Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 34: U.K. Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 35: Italy Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 36: Netherlands Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 37: Asia Pacific Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 38: Asia Pacific Prostate Cancer Vaccines Sales Market Share by Country (2021-2032)
- Figure 39: China Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 40: Japan Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 41: South Korea Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 42: Southeast Asia Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 43: India Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 44: Australia Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 45: South America, Middle East and Africa Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 46: South America, Middle East and Africa Prostate Cancer Vaccines Sales Market Share by Country (2021-2032)
- Figure 47: Brazil Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 48: South Africa Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 49: Saudi Arabia Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 50: Turkey Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 51: Argentina Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 52: UAE Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 53: Egypt Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 54: Chile Prostate Cancer Vaccines Sales and Growth Rate (2021-2032) & (K Units)
- Figure 55: Global Prostate Cancer Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US\$ Million)
- Figure 56: Global Prostate Cancer Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032
- Figure 57: North America Prostate Cancer Vaccines Revenue (2021-2032) & (US\$ Million)
- Figure 58: North America Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 59: Europe Prostate Cancer Vaccines Revenue (2021-2032) & (US\$ Million)
- Figure 60: Europe Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032

- Figure 61: Asia-Pacific Prostate Cancer Vaccines Revenue (2021-2032) & (US\$ Million)
- Figure 62: Asia-Pacific Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 63: South America, Middle East and Africa Prostate Cancer Vaccines Revenue (2021-2032) & (US\$ Million)
- Figure 64: South America, Middle East and Africa Prostate Cancer Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
- Figure 65: Prostate Cancer Vaccines Value Chain
- Figure 66: Manufacturing Cost Structure
- Figure 67: Prostate Cancer Vaccines Production Mode & Process
- Figure 68: Direct Comparison with Distribution Share
- Figure 69: Distributors Profiles
- Figure 70: Years Considered
- Figure 71: Research Process
- Figure 72: Key Executives Interviewed